Novogene Co - Public Comps and Valuation Multiples

Novogene Co Overview

About Novogene Co

Novogene Co Ltd is engaged in providing multi-level scientific research and technical services and solutions for life science basic research, medical and clinical application research, and independent development and innovation of genetic testing medical equipment.

Founded

2011

HQ

Employees

n/a

Website

en.novogene.com

Sectors

Laboratory Services
Genomics & Personalized Medicine
BioTech
DeepTech

Financials

LTM Revenue $318M

LTM EBITDA $56.7M

EV

$631M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Novogene Co Financials

As of September 2025, Novogene Co reported last 12-month revenue of $318M and EBITDA of $56.7M.

In the same period, Novogene Co generated $136M in LTM gross profit and $30.2M in net income.

See Novogene Co valuation multiples based on analyst estimates

Novogene Co P&L

In the most recent fiscal year, Novogene Co reported revenue of $296M and EBITDA of $54.0M.

Novogene Co expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Novogene Co valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$318M	XXX	$296M	XXX	XXX	XXX
Gross Profit	$136M	XXX	$130M	XXX	XXX	XXX
Gross Margin	43%	XXX	44%	XXX	XXX	XXX
EBITDA	$56.7M	XXX	$54.0M	XXX	XXX	XXX
EBITDA Margin	18%	XXX	18%	XXX	XXX	XXX
EBIT	$35.5M	XXX	$31.6M	XXX	XXX	XXX
EBIT Margin	11%	XXX	11%	XXX	XXX	XXX
Net Profit	$30.2M	XXX	$27.6M	XXX	XXX	XXX
Net Margin	9%	XXX	9%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Novogene Co including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $318M. EBITDA for the last twelve months was $56.7M. In the most recent fiscal year, Novogene Co achieved $296M in revenue and $54.0M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$318M	Analyst estimates available to subscribers	$296M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$136M	Analyst estimates available to subscribers	$130M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	42.8% gross margin	Analyst estimates available to subscribers	43.7% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$56.7M	Analyst estimates available to subscribers	$54.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	17.9% EBITDA margin	Analyst estimates available to subscribers	18.2% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$35.5M	Analyst estimates available to subscribers	$31.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	11.2% EBIT margin	Analyst estimates available to subscribers	10.7% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$30.2M	Analyst estimates available to subscribers	$27.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	9.5% net profit margin	Analyst estimates available to subscribers	9.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Novogene Co

This financial data table provides comprehensive performance metrics for Novogene Co, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Novogene Co generated $318M in revenue over the last twelve months.
The company achieved $56.7M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $136M.
Net income over the last twelve months reached $30.2M.

Fiscal Year Performance

In the most recent fiscal year, Novogene Co reported $296M in total revenue.
Fiscal year EBITDA was $54.0M.
The company maintained a gross profit margin of 43.7% in the most recent fiscal year.
EBITDA margin for the fiscal year was 18.2%.
Net profit margin reached 9.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Novogene Co. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Novogene Co Stock Performance

Novogene Co has current market cap of CNY 5.9B (or $831M), and EV of CNY 4.5B (or $631M).

Market Cap Evolution

Novogene Co Stock Data

As of October 17, 2025, Novogene Co's stock price is CNY 14 (or $2).

See Novogene Co trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$631M	$831M	XXX	XXX	XXX	XXX	$0.07

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Novogene Co Valuation Multiples

Novogene Co's trades at 2.1x EV/Revenue multiple, and 11.7x EV/EBITDA.

See valuation multiples for Novogene Co and 15K+ public comps

Novogene Co Financial Valuation Multiples

As of October 17, 2025, Novogene Co has market cap of $831M and EV of $631M.

Equity research analysts estimate Novogene Co's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Novogene Co has a P/E ratio of 27.5x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$831M	XXX	$831M	XXX	XXX	XXX
EV (current)	$631M	XXX	$631M	XXX	XXX	XXX
EV/Revenue	2.0x	XXX	2.1x	XXX	XXX	XXX
EV/EBITDA	11.1x	XXX	11.7x	XXX	XXX	XXX
EV/EBIT	17.8x	XXX	20.0x	XXX	XXX	XXX
EV/Gross Profit	4.6x	XXX	n/a	XXX	XXX	XXX
P/E	27.5x	XXX	30.1x	XXX	XXX	XXX
EV/FCF	n/a	XXX	22.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Novogene Co Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Novogene Co Margins & Growth Rates

Novogene Co's last 12 month revenue growth is 11%

Novogene Co's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Novogene Co's rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Novogene Co's rule of X is 45% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Novogene Co and other 15K+ public comps

Novogene Co Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	11%	XXX	10%	XXX	XXX	XXX
EBITDA Margin	18%	XXX	18%	XXX	XXX	XXX
EBITDA Growth	12%	XXX	7%	XXX	XXX	XXX
Rule of 40	29%	XXX	29%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	45%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	5%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	6%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	33%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial